159 related articles for article (PubMed ID: 26161408)
1. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.
Epelbaum R; Shacham-Shmueli E; Klein B; Agbarya A; Brenner B; Brenner R; Gez E; Golan T; Hubert A; Purim O; Temper M; Tepper E; Voss A; Russell K; Dvir A; Soussan-Gutman L; Stemmer SM; Geva R
Biomed Res Int; 2015; 2015():681653. PubMed ID: 26161408
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience.
Purim O; Beny A; Inbar M; Shulman K; Brenner B; Dudnik E; Bokstein F; Temper M; Limon D; Matceyevsky D; Sarid D; Segal A; Semenisty V; Brenner R; Peretz T; Idelevich E; Pelles-Avraham S; Meirovitz A; Figer A; Russell K; Voss A; Dvir A; Soussan-Gutman L; Hubert A
Target Oncol; 2018 Apr; 13(2):217-226. PubMed ID: 29353436
[TBL] [Abstract][Full Text] [Related]
3. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Dean A; Byrne A; Marinova M; Hayden I
Biomed Res Int; 2016; 2016():4627214. PubMed ID: 27525268
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
6. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
Pishvaian MJ; Blais EM; Brody JR; Lyons E; DeArbeloa P; Hendifar A; Mikhail S; Chung V; Sahai V; Sohal DPS; Bellakbira S; Thach D; Rahib L; Madhavan S; Matrisian LM; Petricoin EF
Lancet Oncol; 2020 Apr; 21(4):508-518. PubMed ID: 32135080
[TBL] [Abstract][Full Text] [Related]
7. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers.
Bharthuar A; Khorana AA; Hutson A; Wang JG; Key NS; Mackman N; Iyer RV
Thromb Res; 2013 Aug; 132(2):180-4. PubMed ID: 23856554
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
9. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
10. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
Propper D; Davidenko I; Bridgewater J; Kupcinskas L; Fittipaldo A; Hillenbach C; Klughammer B; Ducreux M
Ann Oncol; 2014 Jul; 25(7):1384-1390. PubMed ID: 24827134
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy.
Popovtzer A; Sarfaty M; Limon D; Marshack G; Perlow E; Dvir A; Soussan-Gutman L; Stemmer SM
Biomed Res Int; 2015; 2015():614845. PubMed ID: 26448941
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Kruth J; Nissen J; Ernst T; Kripp M; Lukan N; Merx K; Hofmann WK; Hochhaus A; Hofheinz RD
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1845-51. PubMed ID: 20224968
[TBL] [Abstract][Full Text] [Related]
13. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
14. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
[TBL] [Abstract][Full Text] [Related]
15. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
16. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms.
Shibahara H; Tamada S; Goto M; Oda K; Nagino M; Nagasaka T; Batra SK; Hollingsworth MA; Imai K; Nimura Y; Yonezawa S
Am J Surg Pathol; 2004 Mar; 28(3):327-38. PubMed ID: 15104295
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Richards DA; Kuefler PR; Becerra C; Wilfong LS; Gersh RH; Boehm KA; Zhan F; Asmar L; Myrand SP; Hozak RR; Zhao L; Gill JF; Mullaney BP; Obasaju CK; Nicol SJ
Invest New Drugs; 2011 Feb; 29(1):144-53. PubMed ID: 19714296
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary metastasectomy for suspected pancreaticobiliary cancer.
Robinson LA; Tanvetyanon T; Springett G; Fontaine J; Toloza E; Hodul P; Pimiento JM; Malafa M
J Thorac Cardiovasc Surg; 2016 Jul; 152(1):75-82. PubMed ID: 27050555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
